Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01.
Matthew Herper covers medical innovation — both its promise and its perils.
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
This is the online version of The Readout, STAT’s flagship biotech newsletter. Sign up to get it in your inbox.
We have made it! And so have you. This is Adam, Elaine, Matt, and Allison preparing to sign off from JPM26.
And yet — we have one closing act. Join us at 1 p.m. ET tomorrow for a virtual recap of the conference, where we’ll talk about what we learned about the state of biotech, and what it portends for the year ahead.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
At Srivax, we believe in delivering fast, accurate, and relevant news to empower, inform, and engage our readers across the globe. We are an independent digital news platform built for the modern world — where information moves fast, and truth matters.
